BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Statistical Methods in Pre- and Clinical Drug Development: Tumour 
 Growth-Inhibition Model Example - Robert Kozarski\, AstraZeneca
DTSTART:20180426T181500Z
DTEND:20180426T203000Z
UID:TALK72940@talks.cam.ac.uk
CONTACT:Peter Watson
DESCRIPTION:Modelling of tumour-related outcomes to assess treatment effic
 acy applies in both pre- and clinical drug development. Stein et al. [2008
 ] proposed a new paradigm to evaluate cancer therapy effectiveness in an e
 arly clinical drug development. The model decomposes the observed individu
 al tumour measurements over time into two independent component processes 
 of a constant exponential tumour growth/regrowth and regression (inhibitio
 n). The model was also found relevant in modelling pre-clinical in-vivo ex
 perimental data\, establishing a novel approach in describing the observed
  tumour volume dynamics beyond a current practice. During the talk\, the m
 odel pros and cons will be addressed with an example efficacy assessment o
 f the Antibody Drug Conjugate (ADC) cancer therapies on a single study and
  database meta-analysis level.
LOCATION:Amgen Ltd\, Cambridge Science Park\, CB4 0WG
END:VEVENT
END:VCALENDAR